Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICTURE: Predictive Immunological Profiles in Crohn's Disease
NCT03712826Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2022
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
01
Overview
Open-label trial of ustekinumab, infliximab and adalimumab in Crohn's disease (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Immunological profile at Week 14. Planned start Jul 2022; status: withdrawn.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03712826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712826.